Effects of omapatrilat in low, normal, and high renin experimental hypertension

American Journal of Hypertension
N C TrippodoT R Schaeffer

Abstract

Combined inhibition of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE) produces cardiovascular effects greater than those elicited by selective inhibition of either enzyme alone. Dual metalloprotease inhibitors are single molecules that inhibit both NEP and ACE and produce cardiovascular effects in animal models similar to those elicited by the combination of NEP and ACE inhibitors. The purpose of this study was to determined the duration of antihypertensive activity of the dual metalloprotease inhibitor omapatrilat in rodent models of hypertension. Omapatrilat inhibited NEP (Ki = 9 nmol/L) and ACE (Ki = 6 nmol/L) activities in vitro and inhibited the pressor response to angiotensin I in rats after intravenous administration with a potency and duration of action similar to those of the long acting ACE inhibitor fosinoprilat. After single dose administration, omapatrilat lowered mean arterial blood pressure (aortic catheter) in sodium depleted spontaneously hypertensive rats (high renin model) from 148+/-5 to 106+/-3 mm Hg (baseline to 24 h), in deoxycorticosterone acetate-salt hypertensive rats (low renin) from 167+/-4 to 141+/-5 mm Hg and in spontaneously hypertensive rats (normal renin) from 162+/-4 to 138...Continue Reading

Citations

Jun 10, 2000·Current Opinion in Nephrology and Hypertension·G WolfR A Stahl
Jun 8, 2001·Journal of Cardiovascular Pharmacology·F EnseleitT F Lüscher
Nov 22, 2001·Current Hypertension Reports·M J DumoulinA Adam
Nov 22, 2001·Current Hypertension Reports·L V d'Uscio, T F Lüscher
Aug 16, 2001·Journal of Clinical Pharmacology·B K MalhotraC A Knupp
Apr 10, 2002·Diabetes, Obesity & Metabolism·T A Chowdhury, T Khan
Dec 18, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ramaswamy A IyerKishin Kripalani
Mar 8, 2003·Hypertension·Duncan John Campbell
Mar 6, 2004·Clinical and Experimental Hypertension : CHE·Sally A MifsudJennifer L Wilkinson-Berka
Oct 20, 2004·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Tina GröholmIlkka Tikkanen
Nov 10, 2006·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Wolfgang LinzHartmut Rütten
Jun 23, 2010·Nature Reviews. Cardiology·Ludovit Paulis, Thomas Unger
Sep 16, 2000·Current Opinion in Nephrology and Hypertension·J C Burnett
Sep 29, 1999·Current Opinion in Cardiology·G ManciaG Grassi
Jul 18, 2001·Current Opinion in Nephrology and Hypertension·M W Taal, B M Brenner
Feb 22, 2003·Cardiovascular Drug Reviews·Gian Paolo Rossi
Jul 8, 2003·Current Hypertension Reports·Anne ZanchiMichel Burnier
May 18, 2010·Journal of Cardiovascular Pharmacology and Therapeutics·Katherine C Wu, Gary Gerstenblith
Nov 4, 2010·Current Hypertension Reports·Julian Segura, Luis M Ruilope
Oct 22, 2014·Current Heart Failure Reports·Paul M McKie, John C Burnett
Jun 16, 2001·American Journal of Physiology. Renal Physiology·T HannkenG Wolf
Jun 8, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·T QuaschningT F Lüscher
Jul 31, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·F RuschitzkaT F Lüscher
Oct 21, 2000·American Journal of Hypertension·L M BurrellC I Johnston
Oct 16, 1999·Proceedings of the Association of American Physicians·H H Chen, J C Burnett
Jan 16, 2002·Current Hypertension Reports·Thomas QuaschningThomas F Lüscher
Sep 12, 2000·Current Hypertension Reports·J R Asher, A J Naftilan
Oct 5, 2002·Hypertension·Calin V ManiuMargaret M Redfield
Jun 5, 2003·Heart Disease·George Stoupakis, Marc Klapholz
Jun 17, 2003·Journal of Cardiovascular Pharmacology and Therapeutics·Jasmina VaragicEdward D Frohlich
Feb 11, 2004·The Journal of Pharmacology and Experimental Therapeutics·Anthony C SulpizioDavid P Brooks

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.